


Curriculum Vitae



Informazioni personali

Nome(i) / Cognome(i)

Laura Marconato

Indirizzo(i)

Centro Oncologico Veterinario, Via San Lorenzo 1, 40037 Sasso Marconi (BO)

Telefono(i)

+390516751871

Fax

+390516751871

E-mail

marconato@centroncologicovet.it

Cittadinanza

italiana

Data di nascita

05.04.1974

Sesso

femminile

Occupazione
desiderata/Settore
professionale

Medico veterinario, specialista in oncologia medica
(DVM; Dipl. ECVIM-CA [Oncology])

Esperienza professionale

Date

Giugno 2011- ad oggi

Lavoro o posizione ricoperti

Direzione Oncologia Medica Veterinaria

Principali attività e responsabilità

Clinica (70%): inquadramento diagnostico, staging del paziente oncologico, discussione di opzioni terapeutiche. Somministrazione di chemioterapia. Conduzione di trials clinici.
Ricerca applicata alla clinica (30%): network linfoma europeo

Nome e indirizzo del datore di lavoro

Centro Oncologico Veterinario, via San Lorenzo 1-4, 40037 Sasso Marconi (BO), Italia

Tipo di attività o settore	Clinica Veterinaria
Date	Dicembre 2014- ad oggi
Lavoro o posizione ricoperti	Consulente Laboratorio di Analisi Veterinarie La Vallonea
Principali attività e responsabilità	Consulenze di oncologia
Nome e indirizzo del datore di lavoro	Guglielmo Giordano
Tipo di attività o settore	Laboratorio di Analisi Veterinarie
Date	Gennaio 2016- ad oggi
Lavoro o posizione ricoperti	Professore a contratto 35654 - TIROCINIO: MALATTIE CHIRURGICHE DEGLI APPARATI E SISTEMI
Principali attività e responsabilità	Componente del corso integrato CLINICA CHIRURGICA E ORTOPEDIA VETERINARIA (C.I.), VET-09
Nome e indirizzo del datore di lavoro	Università di Bologna, Facoltà di Medicina Veterinaria, Ozzano nell'Emilia (BO)
Tipo di attività o settore	Clinica Veterinaria, Didattica
Date	Maggio 2009- maggio 2011
Lavoro o posizione ricoperti	Co-direzione Dipartimento di Oncologia Medica Veterinaria
Principali attività e responsabilità	Clinica (80%): inquadramento diagnostico, staging del paziente oncologico, discussione di opzioni terapeutiche. Somministrazione di chemioterapia. Ricerca applicata alla clinica (20%): ideazione di trials clinici; carcinoma squamoso orale (gatto), carcinoma infiammatorio (cane), carcinoma uroteliale (cane)
Nome e indirizzo del datore di lavoro	Barbara Kaser-Hotz, Animal Oncology and Imaging Cenmter, Rothusstrasse 2, 6330 Hunenberg ZG, Svizzera
Tipo di attività o settore	Clinica Veterinaria
Date	Settembre 2003- Aprile 2009
Lavoro o posizione ricoperti	Direzione Dipartimento di Oncologia Medica Veterinaria
Principali attività e responsabilità	Clinica: inquadramento diagnostico, staging del paziente oncologico, discussione di opzioni terapeutiche. Somministrazione di chemioterapia.
Nome e indirizzo del datore di lavoro	Francesco Albanese, Clinica Veterinaria Arca, Vico Cacciottoli 1, Napoli, Italia
Tipo di attività o settore	Clinica Veterinaria
Date	2007-2009
Lavoro o posizione ricoperti	Insegnamento Master II livello, Oncologia Medica
Principali attività e responsabilità	Didattica, 96 ore
Nome e indirizzo del datore di lavoro	Facoltà di Medicina Veterinaria, Università di Pisa, Italia
Tipo di attività o settore	Accademica
Date	2004-2005
Lavoro o posizione ricoperti	Professore a contratto
Principali attività e responsabilità	Insegnamento
Nome e indirizzo del datore di lavoro	Facoltà Medicina Veterinaria, Università Federico II, Napoli, Italia

Tipo di attività o settore Accademica
Date 2007-oggi
Lavoro o posizione ricoperti Professore a contratto
Principali attività e responsabilità Insegnamento
Nome e indirizzo del datore di lavoro Facoltà Medicina Veterinaria, Università Bologna, Ozzano nell'Emilia, Italia
Tipo di attività o settore Accademica

Date 2003- oggi
Lavoro o posizione ricoperti Consulente Oncologia
Principali attività e responsabilità Attività di consulenza in oncologia medica veterinaria
Nome e indirizzo del datore di lavoro Varie cliniche ed ambulatori veterinari italiani
Tipo di attività o settore Varie cliniche ed ambulatori veterinari italiani

Date 2003- oggi
Lavoro o posizione ricoperti Relatore in occasione di congressi, incontri di società specialistiche, seminari, corsi
Principali attività e responsabilità Relatore e chairman
Nome e indirizzo del datore di lavoro EV srl
Tipo di attività o settore Società Veterinaria

Date Agosto 1999- agosto 2000
Lavoro o posizione ricoperti Tirocinio post-laurea
Principali attività e responsabilità Rotazioni in medicina interna, oncologia, citologia, laboratorio
Nome e indirizzo del datore di lavoro Claudio Bussadori, Clinica Veterinaria Gran Sasso, via Donatello 26, Milano, Italia
Tipo di attività o settore Clinica Veterinaria

Istruzione e formazione

Date 2014
Titolo della qualifica rilasciata Abilitazione scientifica nazionale alle funzioni di professore di seconda fascia nel Settore Concorsuale 07/H4 α Clinica Medica e Farmacologia Veterinaria

Date 2017
Titolo della qualifica rilasciata Abilitazione scientifica nazionale alle funzioni di professore di prima fascia nel Settore Concorsuale 07/H4 α Clinica Medica e Farmacologia Veterinaria

Date Settembre 2000- agosto 2003
Titolo della qualifica rilasciata 2008: Diplomate ECVIM-CA (Oncology)
Principali tematiche/competenze professionali possedute Approccio al paziente oncologico, staging, inquadramento terapeutico; conoscenza approfondita di farmacoterapia oncologica (chemioterapia); principi di immunoterapia
Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione Veterinary Oncology and Research Center, West Chester, PA (USA)
Livello nella classificazione nazionale o internazionale Diplomata College Europeo Oncologia Medica Veterinaria

Date Settembre 2001- agosto 2003
Titolo della qualifica rilasciata Fellow visitor
Principali tematiche/competenze professionali possedute Training in patologia, patologia tumorale, citologia e immunoistochimica

Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione	Murphy Laboratory, New Bolton Center, University of Pennsylvania, PA (USA)																																																		
Date	1993-1999																																																		
Titolo della qualifica rilasciata	Dottore in medicina veterinaria (110 e lode)																																																		
Principali tematiche/competenze professionali possedute	Studentessa medicina veterinaria																																																		
Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione	Facoltà di Medicina Veterinaria, Università degli Studi di Milano, Italia																																																		
Livello nella classificazione nazionale o internazionale	Medico Veterinario																																																		
Capacità e competenze personali																																																			
Madrelingua(e)	Italiana																																																		
Altra(e) lingua(e)	Inglese, tedesco, francese																																																		
Autovalutazione Livello europeo (*)																																																			
Inglese																																																			
Tedesco																																																			
Francese																																																			
	<table border="1"> <thead> <tr> <th colspan="4">Comprensione</th> <th colspan="4">Parlato</th> <th colspan="2">Scritto</th> </tr> <tr> <th colspan="2">Ascolto</th> <th colspan="2">Lettura</th> <th colspan="2">Interazione orale</th> <th colspan="2">Produzione orale</th> <th colspan="2"></th> </tr> </thead> <tbody> <tr> <td>C2</td> <td>Livello avanzato</td> <td>C2</td> <td>Livello avanzato</td> <td>C2</td> <td>Livello avanzato</td> <td>C2</td> <td>Livello avanzato</td> <td>C2</td> <td>Livello avanzato</td> </tr> <tr> <td>C2</td> <td>Livello avanzato</td> <td>C2</td> <td>Livello avanzato</td> <td>C2</td> <td>Livello avanzato</td> <td>C2</td> <td>Livello avanzato</td> <td>C2</td> <td>Livello avanzato</td> </tr> <tr> <td>B2</td> <td>Livello intermedio</td> <td>B2</td> <td>Livello intermedio</td> <td>B1</td> <td>Livello intermedio</td> <td>B1</td> <td>Livello intermedio</td> <td>A2</td> <td>Livello elementare</td> </tr> </tbody> </table>	Comprensione				Parlato				Scritto		Ascolto		Lettura		Interazione orale		Produzione orale				C2	Livello avanzato	C2	Livello avanzato	C2	Livello avanzato	C2	Livello avanzato	C2	Livello avanzato	C2	Livello avanzato	C2	Livello avanzato	C2	Livello avanzato	C2	Livello avanzato	C2	Livello avanzato	B2	Livello intermedio	B2	Livello intermedio	B1	Livello intermedio	B1	Livello intermedio	A2	Livello elementare
Comprensione				Parlato				Scritto																																											
Ascolto		Lettura		Interazione orale		Produzione orale																																													
C2	Livello avanzato	C2	Livello avanzato	C2	Livello avanzato	C2	Livello avanzato	C2	Livello avanzato																																										
C2	Livello avanzato	C2	Livello avanzato	C2	Livello avanzato	C2	Livello avanzato	C2	Livello avanzato																																										
B2	Livello intermedio	B2	Livello intermedio	B1	Livello intermedio	B1	Livello intermedio	A2	Livello elementare																																										
Capacità e competenze sociali	Collaborazione da anni presso Cliniche Veterinarie, lavorando in stretto contatto con veterinari italiani e stranieri																																																		
Capacità e competenze organizzative	Frequentemente coinvolta nell'organizzazione di eventi scientifici inerenti l'oncologia veterinaria in Italia (SCIVAC, la più grande società europea per i veterinari) Presidente della Società di Oncologia Veterinaria (SIONCOV) Stesura di lavori scientifici per riviste nazionali ed internazionali (V. allegato). Preparazione di lavori presentati a congressi scientifici nazionali ed internazionali (V. allegato). Membro di Società scientifiche nazionali ed internazionali (V. allegato)																																																		
Capacità e competenze tecniche																																																			
Capacità e competenze informatiche	Utilizzo PC , MAC																																																		
Capacità e competenze artistiche																																																			
Altre capacità e competenze																																																			
Patente	Patente B																																																		
Ulteriori informazioni	Inserire qui ogni altra informazione utile, ad esempio persone di riferimento, referenze, ecc. (facoltativo, v. istruzioni)																																																		
Allegati	ELENCO PUBBLICAZIONI SCIENTIFICHE (ALL.1) ELENCO RELAZIONI ITALIANE E STRANIERE (ALL.2) ELENCO APPARTENENZA A SOCIET SCIENTIFICHE (ALL.3)																																																		

Autorizzo il trattamento dei miei dati personali ai sensi del Decreto Legislativo 30 giugno 2003, n. 196 "Codice in materia di protezione dei dati personali (facoltativo)".

Firma | Laura Marconato

A handwritten signature in black ink, appearing to read 'Laura Marconato', written in a cursive style.

10 marzo 2016

PUBLICATIONS

ACCEPTED/PUBLISHED ORIGINAL ARTICLES ON PEER-REVIEWED JOURNALS:

- 1.) EIPH: postrace endoscopic evaluation of Standardbreds and Thoroughbreds. Birks EK, Shuler KM, Soma LR, Martin BB, **Marconato L**, Del Piero F, Teleis DC, Schar D, Hessinger AE, Uboh CE. Equine Veterinary Journal Suppl 2002 Sep; (34):375-8.
- 2.) Photodynamic therapy creates fluence rate-dependent gradients in the intra-tumoral spatial distribution of oxygen. Busch TM, Wileyto EP, Emanuele MJ, DelPiero F, Marconato L, Glatstein E, Koch CJ. Cancer Research 2002 Dec 15, 62 (24); 7273-9.
- 3.) Extra-genital venereal transmissible tumor associated with circulating neoplastic cells in an immunologically compromised dog. Albanese F, Salerni FL, Giordano S, Marconato L. Veterinary and Comparative Oncology 4(1):57-62, 2005.
- 4.) Gastric dilatation-volvulus as complication after surgical removal of a splenic hemangiosarcoma in a dog. **Marconato L**. Journal of Veterinary Medicine Series A Physiol Pathol Clin Med. 2006 Sep;53(7):371-4.
- 5.) Diagnostic value of cytologic examination of gastrointestinal tumors in dogs and cats: retrospective survey in 83 cases (2001-2004). Bonfanti U, Bertazzolo W, Bottero E, De Lorenzi D, **Marconato L**, Masserdotti C, Zatelli A, Zini E. Journal of the American Veterinary Medical Association. 2006 Oct 1; 229(7):1130-3.
- 6.) Unusual dermatologic toxicity of hydroxyurea in two dogs with spontaneously occurring tumours. **Marconato L**, Bonfanti U, Fileccia I. Journal of Small Animal Practice 2007 Sep; 48(9): 514-517.
- 7.) Postsurgical intraincisional 5-fluorouracil in dogs with incompletely resected, extremity malignant spindle cell tumors: a pilot study. **Marconato L**, Comastri S, Lorenzo MR, Abramo F, Bettini G. Veterinary and Comparative Oncology. 2007 Dec; 5(4):239-249.
- 8.) Paraneoplastic alopecia associated with hepatocellular carcinoma in a cat. **Marconato L**, Albanese F, Viacava P, Marchetti V, Abramo F. Veterinary Dermatology 2007; 18(4): 267-271.
- 9.) Cytosine arabinoside in addition to VCAA-based protocols for the treatment of canine lymphoma with bone marrow involvement: does it make the difference? **Marconato L**, Bonfanti U, Stefanello D, Lorenzo MR, Romanelli G, Comazzi S, Zini E. Veterinary and Comparative Oncology 2008; 6(2): 80-89.
- 10.) Adjuvant Gemcitabine after surgical removal of aggressive malignant mammary tumors in dogs. Marconato L, Lorenzo RM, Abramo F, Ratto A, Zini E. Veterinary and Comparative Oncology 2008; 6(2): 90-101.
- 11.) Quali-quantitative aberrant phenotypes in different subtypes of canine lymphoma by flow cytometry. Gelain ME, Mazzilli M, Riondato F, **Marconato L**, Comazzi S. Veterinary Immunology and Immunopathology 2008; 121: 179-188.
- 12.) Analysis of prognostic factors associated with feline injection-site sarcomas. Romanelli G, **Marconato L**, Olivero D, Massari F, Zini E. Journal of the American Veterinary Medical Association 2008 Apr 15; 232(8): 1193-9.
- 13.) Cytomorphometric approach for predicting regional lymph node micrometastatic load in canine mast cell tumors: preliminary results. **Marconato L**, Marchetti V, Francione D, Masserdotti C, Gregori M, Leotta R, Abramo F. Veterinary and Comparative Oncology. 2008; 6(3): 162-170.

14.) Clinico-pathological features and outcome for dogs with mast cell tumors and bone marrow involvement. **Marconato L**, Bettini G, Giacoboni C, Romanelli G, Cesari A, Zatelli A, Zini E. Journal of Veterinary Internal Medicine 2008; 22:1001-1007.

15.) TTF-1 (Thyroid Transcription Factor-1) immunohistochemistry: diagnostic tool and malignancy marker in canine malignant lung tumours. Bettini G, **Marconato L**, Morini M, Ferrari F. Veterinary and Comparative Oncology 2009; 7(1):28-37.

16.) Association between waste management and cancer in companion animals. **Marconato L**, Leo C, Girelli R, Salvi S, Abramo F, Bettini G, Comazzi S, Nardi P, Albanese F, Zini E. Journal of Veterinary Internal Medicine 2009; 23(3):564-9.

17.) Predictors of survival in dogs with mammary inflammatory carcinoma: a retrospective analysis of 43 cases (2003-2008). **Marconato L**, Romanelli G, Stefanello D, Giacoboni C, Bonfanti U, Bettini G, Finotello R, Verganti S, Valenti P, Ciaramella L, Zini E. Journal of the American Veterinary Medical Association 2009; 235(8):967-72.

18.) Comparative expression pathway analysis of human and canine mammary tumors. Uva P, Aurisicchio L, Watters J, Loboda A, Kulkarni A, Castle J, Palombo F, Viti V, Mesiti G, Zappulli V, **Marconato L**, Abramo F, Ciliberto G, Lahm A, La Monica N, de Rinaldis E. BMC Genomics. 2009; 10:135

19.) Serum lactate dehydrogenase activity in canine malignancies. **Marconato L**, Crispino G, Finotello R, Mazzotti S, Salerno F, Zini E. Veterinary and Comparative Oncology 2009; 7(4): 236-243.

20.) Clinical relevance of serial determinations of lactate dehydrogenase activity used to predict recurrence in dogs with lymphoma. **Marconato L**, Crispino G, Finotello R, Mazzotti S, Zini E. Journal of the American Veterinary Medical Association. 2010;236(9):969-74.

21.) Association between environmental dust exposure and lung cancer in dogs. Bettini G, Morini M, **Marconato L**, Marcato PS, Zini E. The Veterinary Journal. 2010;186:364-369.

22.) EGFR expression is predictive of poor prognosis in feline cutaneous squamous cell carcinoma. Sabattini S, **Marconato L**, Zoff A, Morini M, Scarpa F, Capitani O, Bettini G. Journal of Feline Medicine and Surgery. 2010; 12: 760-8.

23.) Canine medium macronucleated cell/ marginal zone lymphoma: description of 16 cases. Stefanello D, Valenti P, Zini E, Roccabianca P, Avallone G, Comazzi S, Caniatti M, **Marconato L**. Journal of Veterinary Internal Medicine. 2011; 25(1):90-3.

24.) Immunophenotype predicts survival time in dogs with chronic lymphocytic leukemia. Comazzi S, Gelain ME, Martini V, Riondato F, Miniscalco B, **Marconato L**, Stefanello D, Mortarino M. Journal of Veterinary Internal Medicine. 2011; 25(1):100-6.

25.) Predictors of long-term survival in dogs with high grade multicentric lymphoma. **Marconato L**, Stefanello D, Valenti P, Bonfanti U, Comazzi S, Roccabianca P, Caniatti M, Romanelli G, Massari F, Zini E. Journal of the American Veterinary Medical Association. 2011; 238(4):480-5.

26.) Toxic effects and antitumor response of gemcitabine in combination with piroxicam treatment in dogs with transitional cell carcinoma of the urinary bladder. **Marconato L**, Zini E, Lindner D, Suslak-Brown L, Nelson V, Jeglum KA. Journal of the American Veterinary Medical Association. 2011;238(8):1004-10.

27.) The staging and treatment of multicentric high grade lymphoma in dogs: a look over the past decade and future perspectives. Review. **Marconato L**. The Veterinary Journal. 2011; 188(1):34-8.

- 28.) New concepts in human oncology: is it possible to use them in veterinary medicine as well? **L. Marconato**, K. Ruess-Melzer, J. Buchholz, B. Kaser-Hotz. Schweizer Archiv für Tierheilkunde. 2011 Aug;153(8):351-60.
- 29.) Immunophenotype-related microRNA expression in canine chronic lymphocytic leukemia. Gioia G, Mortarino M, Gelain ME, Albonico F, Ciusani E, Forno I, **Marconato L**, Martini V, Comazzi S. Veterinary Immunology and Immunopathology 2011;142(3-4):228-35.
- 30.) Chemotherapy and radiation therapy in 4 dogs with muscle invasive transitional cell carcinoma of the urinary tract. **Marconato L**, Nitzl D, Melzer-Ruess K, Keller M, Buchholz J. Canadian Veterinary Journal 2012 Aug;53(8):875-9.
- 31.) Multimodal therapeutic approach and interdisciplinary challenge for the treatment of unresectable head and neck squamous cell carcinoma in 6 cats: a pilot study. **Marconato L**; Buchholz J; Keller M; Bettini G; Valenti P; Kaser Hotz B. Veterinary and Comparative Oncology 2013 Jun;11(2):101-12.
- 32.) Use of histologic margin evaluation to predict recurrence of cutaneous malignant tumors in dogs and cats after surgical excision. Scarpa F, Sabattini S, **Marconato L**, Capitani O, Morini M, Bettini G. Journal of the American Veterinary Medical Association 2012; 240(10):1181-7.
- 33.) The dog as a possible animal model for human non-Hodgkin lymphoma: a review. **Marconato L**, Gelain ME, Comazzi S. Hematol Oncol, 2013 Mar;31(1):1-9.
- 34.) EGFR overexpression in canine primary lung cancer: pathogenetic implications and impact on survival. Sabattini S; Mancini F; **Marconato L**; Bacci B; Rossi F; Vignoli M; Bettini G. Veterinary and Comparative Oncology. 2014 Sep;12(3):237-48.
- 35.) Metastatic cancer of unknown primary in 21 dogs. Rossi F, Aresu L, Vignoli M, Buracco P, Bettini G, Ferro S, Gattino F, Ghiani F, Costantino R, Ressel L, Bellei E, **Marconato L**. Veterinary and Comparative Oncology. 2015 Mar;13(1):11-9.
- 36.) Whole body computed tomographic characteristics of skeletal and cardiac muscular metastatic neoplasia in dogs and cats. Vignoli M, Terragni R, Rossi F, Frühauf L, Bacci B, Ressel L, Capitani O, **Marconato L**. Veterinary and Radiology Ultrasound. 2013 May-Jun;54(3):223-30.
- 37.) Assessment of bone marrow infiltration diagnosed by flow cytometry in canine large B cell lymphoma: Prognostic significance and proposal of a cut-off value. **Marconato L**, Martini V, Aresu L, Sampaolo M, Valentini F, Rinaldi V, Stefano Comazzi S. The Veterinary Journal, 2013 Sep;197(3):776-81.
- 38.) Canine indolent and aggressive lymphoma: Clinical spectrum with histologic correlation. Aresu L, Martini V, Rossi F, Vignoli M, Sampaolo M, Aricò A, Laganga P, Pierini A, Frayssinet P, Mantovani R, **Marconato L**. Veterinary and Comparative Oncology. In press.
- 39.) Concordance of c-kit Mutational Status in Matched Primary and Metastatic Cutaneous Canine Mast Cell Tumors at Baseline: Implications for Clinical Practice. **Marconato L**, Zorzan E, Giantin M, Di Palma S, Cancedda S, Dacasto M. Journal of Veterinary Internal Medicine, 2014 Mar-Apr;28(2):547-53.
- 40.) First meeting of the European canine lymphoma group. Workshop: state of the art and comparative aspects in canine lymphoma. CH-Lugano, 22 June 2013. First meeting of the European canine lymphoma group. Comazzi S, Guscelli F, **Marconato L**. Hematol Oncol. 2014 Jun;32(2):68-71
- 41.) Randomized, Placebo-Controlled, Double-Blinded Chemoimmunotherapy Clinical Trial in a Pet Dog Model of Diffuse Large B-cell Lymphoma. **Marconato L**, Frayssinet P, Rouquet N, Comazzi S, Leone VF, Laganga P, Rossi F, Vignoli M, Pezzoli L, Aresu L. Clinical Cancer Research, 2014 Feb 1;20(3):668-77.
- 42.) Minimal residual disease detection by flow cytometry and PARR in lymph node, peripheral blood and bone marrow following chemotherapy in dogs with diffuse large B-cell lymphoma. Aresu L, Aricò

- A, Ferraresso S, Martini V, Comazzi S, Riondato F, Giantin M, Dacasto M, Guadagnin E, Frayssinet P, Rouquet N, Drigo M, **Marconato L**. The Veterinary Journal. 2014 May;200(2):318-24.
- 43.) Epigenetic silencing of TFPI-2 in canine Diffuse Large B-cell lymphoma. Ferraresso S, Bresolin S, Comazzi S, Gelain ME, Riondato F, Bargelloni L, **Marconato L**, te Kronnie G, Aresu L. PlosONE, 2014 Apr 2;9(4):e92707.
- 44.) Global gene expression analysis of canine cutaneous mast cell tumor: could molecular profiling be useful for subtype classification and prognostication? Giantin M, Granato A, Baratto C, **Marconato L**, Vascellari M, Morello E, Vercelli A, Mutinelli F, Dacasto M. PlosONE, 2014 Apr 18;9(4):e95481.
- 45.) Platelet-derived growth factors and receptors in canine lymphoma. A. Aricò, E. Guadagnin, S. Ferraresso, M.E. Gelain, S. Iussich, B.C. Rütgen, S. Mazzariol, **L. Marconato**, L. Aresu. Journal of Comparative Pathology. 2014 Nov;151(4):322-8.
- 46.) Comparison of 2- and 3-category histologic grading systems for predicting the presence of metastasis at the time of initial evaluation in dogs with cutaneous mast cell tumors: 386 cases (2009-2014). D. Stefanello; P. Buracco; S. Sabbatini; R. Finotello; C. Giudice; V. Grieco; S. Iussich; M. Tursi; T. Scase; S. Di Palma; G. Bettini; R. Ferrari; M. Martano; F. Gattino; M. Marrington; M. Mazzola; ME. Vasconi; M. Annoni; **L. Marconato**. Journal of the American Veterinary Medical Association. 2015 Apr 1;246(7):765-9.
- 47.) Efficacy and side effects of radiation therapy in comparison with radiation therapy and temozolomide in the treatment of measurable canine malignant melanoma. Cancedda S, Rohrer-Bley C, Aresu L, Dacasto M, Leone VF, Pizzoni S, Gracis M, **Marconato L**. Veterinary and Comparative Oncology. In press.
- 48.) Array-based comparative genomic hybridization analysis reveals chromosomal copy number aberrations associated with clinical outcome in canine diffuse large B-cell lymphoma. Aricò A, Ferraresso S, Bresolin S, **Marconato L**, Comazzi S, Te Kronnie G, Aresu L. PlosONE. 2014 Nov 5;9(11):e111817.
- 49.) Prognostic factors in canine acute leukemias: a retrospective study of 71 cases. Novacco M, Comazzi S, **Marconato L**, Cozzi M, Stefanello D, Aresu L, Martini V. Veterinary and Comparative Oncology. In press.
- 50.) THE EUROPEAN CANINE LYMPHOMA NETWORK: A COLLABORATIVE INITIATIVE TO GENERATE CONSENSUS GUIDELINES FOR THE DIAGNOSIS AND THERAPY OF CANINE LYMPHOMA. S. Comazzi, **L. Marconato**, D. Argyle, L. Aresu, M. Stirn, I. Grant, F. Guscetti, T.Hendrickx , C. Ibsch, J. Lawrence, G. Polton, E. Teske on behalf of The European Canine Lymphoma Network. Veterinary and Comparative Oncology. 2015 Dec;13(4):494-7.
- 51.) Comparison of doxorubicin-cyclophosphamide and doxorubicin-dacarbazine for the adjuvant treatment of canine hemangiosarcoma. Finotello R, Stefanello D, Zini E, **Marconato L**. Veterinary and Comparative Oncology. In press.
- 52.) An open-label phase 1 dose-escalation clinical trial to determine the maximally tolerated dose and dose-limiting toxicities of a single intravenous gemcitabine administration in dogs with advanced solid tumors. **Marconato L**, Finotello R, Bonfanti U, Dacasto M, Beatrice L, Pizzoni S, Leone VF, Balestra G, Furlanello T, Rohrer Bley C, Aresu L. Journal of Veterinary Internal Medicine. 2015 Mar-Apr; 29(2):620-5.
- 53.) Perspectives on the design of clinical trials for targeted therapies and immunotherapy in veterinary oncology. **Marconato L**, Buracco P, Aresu L. The Veterinary Journal 2015 Mar 3. pii: S1090-0233(15)00094-5.
- 54.) Canine small clear cell/ T-zone lymphoma: clinical presentation and outcome in a retrospective case series. Martini V, **Marconato L**, Poggi A, Riondato F, Aresu L, Cozzi M, Comazzi S. Veterinary and Comparative Oncology. In press.
- 55.) Chronic lymphocytic leukemia transformation into high grade lymphoma: a description of Richter syndrome in 8 dogs. Comazzi S, Martini V, Riondato F, Poggi A, Stefanello D, **Marconato L**,

Albonico F, Gelain ME. Veterinary and Comparative Oncology. In press.

56.) Peripheral blood lymphocyte/monocyte ratio as a useful prognostic factor in dogs with diffuse large B-cell lymphoma receiving chemoimmunotherapy. **Marconato L**, Martini V, Stefanello D, Moretti P, Ferrari R, Comazzi S, Laganga P, Riondato F, Aresu L. The Veterinary Journal, 2015 Nov;206(2):226-30.

57.) Enhanced therapeutic effect of APAVAC immunotherapy in combination with dose-intense chemotherapy in dogs with advanced indolent B-cell lymphoma. **Marconato L**, Stefanello D, Sabattini S, Comazzi S, Riondato F, Laganga P, Frayssinet P, Pizzoni S, Rouquet N, Aresu L. Vaccine, 2015 Sep 22;33(39):5080-6.

58.) Hypofractionated Radiotherapy for Macroscopic Canine Soft Tissue Sarcoma: A Retrospective Study of 50 Cases Treated with a 5x6 Gy protocol with or without metronomic chemotherapy. Cancedda S, **Marconato L**, Meier V, Laganga P, Roos M, Leone VF, Rossi F, Rohrer Bley C. Veterinary Radiology & Ultrasound, in press.

59.) Transformation of canine lymphoma/leukemia to more aggressive diseases: anecdotes or reality? Comazzi S, Aresu L, **Marconato L**. Frontiers in Veterinary Science, 2015 Oct 7;2:42.

60.) A retrospective analysis of chemotherapy switch suggests improved outcome in surgically removed, biologically aggressive canine haemangiosarcoma. Finotello R, Henriques J, Sabattini S, Stefanello D, Felisberto R, Pizzoni S, Ferrari R, **Marconato L**. Veterinary and Comparative Oncology. in press

61.) DNA methylation and targeted sequencing of methyltransferases family genes in canine acute myeloid leukemia, modeling human myeloid leukemia. Bronzini I, Aresu L, Paganin M, Marchioretto L, Comazzi S, Cian F, Riondato F, **Marconato L**, Martini V, te Kronnie G. VCO. In press.

62.) Transcriptomic analysis identified up-regulation of a solute carrier transporter and UDP glucuronosyltransferases in dogs with aggressive cutaneous mast cell tumors. Giantin M, Baratto C, **Marconato L**, Vascellari M, Mutinelli F, Dacasto M, Granato A. The Veterinary Journal, in press.

63.) Conformity and consensus in the diagnosis, staging and follow-up evaluation of canine nodal lymphoma: a systematic review of the last 15 years of published literature. **Marconato L**, Polton GA, Sabattini S, Dacasto M, Garden OA, Grant I, Hendrickx T, Henriques J, Lubas G, Morello E, Stefanello D, Comazzi S, on behalf of the European Canine Lymphoma Network. VCO. In press

64.) Features and prognostic impact of distant metastases in 45 dogs with de novo stage IV cutaneous mast cell tumors: a prospective study. Pizzoni S, Sabattini S, Stefanello D, Dentini A, Ferrari R, Dacasto M, Giantin M, Laganga P, Amati M, Tortorella G, **Marconato L**. VCO. In press

65.) The use of low-dose metronomic chemotherapy in dogs –insight into a modern cancer field: a review. Gaspar TB, Henriques J, **Marconato L**, Queiroga FL. VCO. In press.

66.) Feline large granular lymphocyte lymphoma: An Italian Society of Veterinary Oncology (SIONCOV) retrospective study. Finotello R, Vasconi ME, Sabattini S, Agnoli C, Giacoboni C, Annoni M, Dentini A, Bettini G, Guazzi P, Stefanello D, Bottero E, Mesto P, Marinelli R, De Feo C, **Marconato L**. Vet Comp Oncol. 2017 May 29. doi: 10.1111/vco.12325.

ACCEPTED/PUBLISHED ORIGINAL ARTICLES ON NON PEER-REVIEWED JOURNALS:

1.) Cutaneous paraneoplastic syndromes: point of intersection between dermatologist and oncologist. **Marconato L**, Albanese F, Lorenzo MR. Veterinaria. 2006 June; 3: 9-15.

2.) Chemotherapy and molecular therapy in veterinary oncology: state of the art. Marconato L. Veterinaria. 2007 June; 21(3): 9-17.

3.) Diffuse histiocytic sarcoma with circulating neoplastic cells in a dog. **Marconato L**, Comazzi S, Esposito R, Ciaramella L, Crispino G, Finotello R. Veterinaria. 2008 December, 22(6):1-4.

4.) Un caso di gastrinoma in un cane. Crispino G, Rossi F, Mazzotti S, Finotello R, Abramo F, Magni G, **Marconato L.** Veterinaria 2009; 23(6): 41-44.

5.) Lesioni cutanee indotte dal sole nel gatto: dalla cheratosi attinica al carcinoma squamoso. Patogenesi, aspetti clinico-patologici e terapia. **Marconato L.**, Abramo F. Veterinaria. 2010; 24(3):7-24.

6.) Staging iniziale e finale del linfoma del cane: l'essenziale in breve e alla portata di tutti. **Marconato L.** Veterinaria 2016; 30(1):1-9.

LECTURES BY INVITATION AT NATIONAL SCIENTIFIC MEETINGS:

- 2004** Veterinary Medical Association, Napoli, Italy
"Oncologic emergencies"
- 2005** SCIVAC, Avellino, Italy
"Histiocytic disorders, an emerging problem"
"Paraneoplastic syndromes"
"Splenic tumors- beyond splenectomy"
- 2005** SIMIV-SCIVAC, Cremona, Italy
"Canine lymphoma: staging procedure, prognostic factors, therapy"
- 2005** SCIVAC, Cagliari, Italy
"Canine lymphoma: staging and therapy"
"Paraneoplastic syndromes"
"Splenic tumors- beyond splenectomy"
- 2005** ATOVELP, Sesto Fiorentino, Italy
"Canine mammary tumors"
"Feline mammary tumors"
"Tumors of the male reproductive tract"
"Oncologic emergencies: how to diagnose and how to treat them"
"Chemotherapy-related adverse events"
- 2006** SIONCOV, Cremona, Italy
"Canine lymphoma: introduction, staging procedure and therapy"
- 2006** SCIVAC-SINUUV-SIMIV, Sesto San Giovanni, Italy
"Urinary tract tumors: a well-reasoned diagnostic work-up"
"Medical therapy of urinary tract tumors: past, present and future"
- 2006** SIONCOV, Cremona, Italy
"Medical treatment of osteosarcoma: chemotherapy and new drugs"
- 2006** SCIVAC, Cremona, Italy
"Histiocytic disorders"
"Plasma cell tumors"
- 2006** Circolo Veterinario Bolognese, Bologna, Italy
"Canine lymphoma: staging procedure"
"Practical management of the lymphomatous patient"
"Chronic lymphocytic leukemia: is chemotherapy always necessary?"
- 2007** Circolo Veterinario Campano, Napoli, Italy
"Oncologic patient's and client's approach"
"Chemotherapy: tricks to keep the patient and the client"
"The oncologic patient: behind the scenes"

- 2007** SCIVAC (56° Congresso Internazionale Multisala), Rimini, Italy
Specialized workshop: medical oncologist, surgeon and pathologist: synergy of three professionals in the canine mammary neoplasia
"Chemotherapy for the treatment of the most common gastrointestinal tumors: state of the art"
"Cutaneous tumors of lymphocytic origin"
- 2007** Merial, Rom, Italy
"The oncologic patient: what to do and what to avoid"
- 2007** SIONCOV, Cremona, Italy
"Malignant hypercalcemia"
"Haematologic paraneoplastic syndromes"
- 2008** SIODOV, Cremona, Italy
"Clinical pathology of neoplastic lesions of the oral cavity, lips, and tongue"
"Cancer of the oral cavity: diagnosis and treatment options"
"Surgery, radiation therapy, and chemotherapy: which one?"
- 2008** SCIVAC 58° International Congress, Milan, Italy
"Approach to the oncologic patient: can you or must you choose?"
"New medical therapies: fiction or reality?"
- 2008** SCIVAC, Cremona, Italy
"Medical approach to oral tumors: challenge or therapeutic disappointment?"
- 2008** SIONCOV, Cremona, Italy
"Clinical staging of canine mast cell tumors"
- 2008** Associazione Veterinari Modenesi, Modena, Italy
"New medical therapies in oncology"
"Chemotherapy-related adverse events"
"Canine lymphoma: staging procedure"
"Practical management of the lymphomatous patient"
"Feline lymphoma: staging and therapy"
- 2008** Ordine Medici Veterinari Forlì, Forlì, Italy
"New medical therapies in oncology"
"Canine lymphoma: staging procedure"
"Practical management of the lymphomatous patient"
"Feline lymphoma: staging and therapy"
"Medical treatment for osteosarcoma"
"Mast cell tumors: staging and therapy"
- 2009** SIONCOV, Cremona, Italy
"Palliative chemotherapy"
- 2009** SCIVAC, Cremona, Italy
"Lymphoma: new diagnostic tools and therapy"
"Mammary gland tumors- what you need to know"
"Cutaneous and visceral mast cell tumors"
"Oral squamous cell carcinoma: disappointment or therapeutic challenge?"
- 2009** SCIVAC 62° International Congress, Rimini, Italy
"Mammary and genital tumors- when is chemotherapy an option?"
"Treatment-related toxicity in lymphoma protocols: patient, owner, and clinician"
- 2009** SIONCOV, Cremona, Italy
"Principles of medical treatment (strategies, combination schedules, multimodal approach)"

“Chemotherapeutic agents: alkylating agents, antitumoral antibiotics”

- 2010** SICIV, Cremona, Italy
“Feline lymphoma: the point of view of the medical oncologist”
- 2010** SIONCOV-SVIDI, Cremona, Italy
“Classification of pulmonary and pleural tumors. Clinical presentation and staging.”
- 2010** SCIVAC, Cremona, Italy
“Basic science of oncology”
- 2011** SIONCOV, Cremona, Italy
“Rare and difficult tumors”
- 2011** SCIVAC 69° International Congress, Rimini, Italy
“Etiology, clinical presentation and staging of urinary tract neoplasia”
“Medical treatment of urinary tract neoplasia”
- 2012** SIONCOV, Cremona, Italy
“Hemangiosarcoma”
- 2012** SCIVAC, Pescara, Italy
“Profession: medical oncologist”
- 2012** IOR, Bellinzona, Switzerland
“Clinical management of canine lymphoma”
- 2012** SCIVAC 73° International Congress, Rimini, Italy
“Canine mast cell tumor: prognostic factors”
“Antitumoral therapies for canine mast cell tumors: the past, the present and the future”
“Feline mast cell tumors: available therapies”
- 2013** SCIVAC, Ancona, Italy
“Profession: medical oncologist”
- 2013** SIONCOV, Cremona, Italy
“Treatment options for metastatic disease”
- 2013** SCIVAC 79° National Congress, Palermo, Italy
“Staging the oncologic patient”
“Chemotherapy; when and why”
“What’s new for canine lymphoma?”
“How should we treat feline lymphoma?”
“Mammary tumors”
“Histiocytic tumors”
- 2013** SIONCOV, Cremona, Italy
“Inflammatory carcinoma”
- 2014** Merial, Andalo
“Antitumoral treatment in the geriatric patient”
SIONCOV, Padova, Italy
“Malignant hypercalcemia”
“Febrile neutropenia”
- SIODOV, Cremona, Italy
“Treatment of canine and feline oral tumors”
- SCIVAC, Introduction to oncology, Milano, Italy

“Hemangiosarcoma”
“Canine lymphoma”
“Feline lymphoma”
“Mast cell tumor”
“Mammary tumors in dogs and cats”
“Staging”
“Chemotherapy, safe handling”
“Histiocytic tumors”

2015

SCIVAC, Cremona, Italy
Director Oncology Course, ESVPS approved (April)

SIONCOV, Cremona, Italy
“Initial and end-staging in canine lymphoma: therapeutic implications”

SCIVAC, Cremona, Italy
Director Oncology Course, ESVPS approved (July)

SCIVAC, Bologna, Italy
Canine mast cell tumor

SIONCOV, Cremona, Italy
“Radiation therapy in the multimodal strategy: clinical cases”

SCIVAC, Cremona, Italy
Oncology Course, ESVPS approved (November)

2016

MERIAL, Andalo
“10 oncology rules”

SCIVAC, Cremona, Italy
Oncology Course, ESVPS approved (February)

SCIVAC, Verona, Italy
International Congress, Oncology in 2016
“Feline oral squamous cell carcinoma, a new point of view”
“Mast cell tumor: correct indication for adjuvant treatment”
“Steroids in veterinary oncology: pros and cons”

SCIVAC, 77° International Congress, Rimini, Italy
“Canine lymphoma: pre-therapeutic considerations”

SCIVAC, Cremona, Italy
Oncology Course, ESVPS approved (June)

SCIVAC, Cremona, Italy
Masterclass “50 shadows of mast cell tumors”

SIONCOV, Cremona, Italy
“Feline oral squamous cell carcinoma: be positive”

SCIVAC, Firenze, Italy
Introduction to Oncology
“Hemangiosarcoma”
“Canine lymphoma”
“Feline lymphoma”
“Mast cell tumor”
“Mammary tumors in dogs and cats”
“Staging”
“Chemotherapy, safe handling”

2017

SIONCOV, Cremona, Italy

“Feline LGL”

“Immunotherapy for canine lymphoma: updates and guidelines”

ORAL PRESENTATIONS AT INTERNATIONAL SCIENTIFIC MEETINGS:

- 1.) Diagnostic imaging for the identification of cardiac tumors in humans and dogs. C. Bussadori, S. Biasi, C. Quintavalla, D. Pradelli, L. Marconato 13th Ljudevit Jurak International Symposium on Comparative Pathology, Zagreb, Croatia, 7-8th June, 2002. Abstract published in the proceedings.
- 2.) A phase I clinical trial of high dose gemcitabine in 33 dogs with transitional cell carcinoma. Marconato L, Lindner DL, Suslak-Brown L, Nelson V, Jeglum KA. 22nd Annual Conference of the Veterinary Cancer Society, New York, NY-September 12-15th, 2002. Abstract published in the proceedings.
- 3.) Diagnostic value of cytologic examination of gastrointestinal tumors in dogs and cats: retrospective survey in 83 cases (2001-2004). U. Bonfanti, W. Bertazzolo, E. Bottero, D. De Lorenzi, L. Marconato, C. Masserdotti, A. Zatelli, E. Zini. 7th Annual Meeting of the European Society of Veterinary Clinical Pathology and the European College of Veterinary Clinical Pathology, Utrecht University, Utrecht, The Netherlands, June 2005. Abstract published in the proceedings.
- 4.) Flow cytometric evaluation of morphological features and antigenic pattern in canine lymphoma. M. E. Gelain, M. Mazzili, F. Riondato, L. Marconato, S. Comazzi. Annual Conference of the European Society of Veterinary Clinical Pathologists, Cambridge, England, September 5-8th, 2006.
- 5.) Adjuvant gemcitabine after surgical removal of aggressive malignant mammary tumors in dogs. L. Marconato, MR Lorenzo, F Abramo, A Ratto, E Zini. Annual Conference of the European Society of Veterinary Oncology, Queen's College, Cambridge, England, March 23-25th, 2007, p 16. Abstract published in the proceedings.
- 6.) Evaluation of Imatinib effect in an ex vivo culture system of skin samples from dog with grade II mastocytoma. Rossi G., Magi E., Mari S., Marconato L., Renzoni G., Bertani C. 25th Annual Meeting of the European Society of Veterinary Pathology, Ludwig Maximilians University, Munich, Germany, August 29th - September 1st, 2007. Abstract published in the proceedings.
- 7.) Clinico-pathological features and treatment options for canine mast cell tumors with bone marrow involvement in the imatinib era: disappointment or challenge? L. Marconato, G. Bettini, C. Giacoboni, G. Romanelli, A. Cesari, A. Zatelli, E. Zini. VCS-ESVONC meeting, Copenhagen 28 February- 1 March 2008. Abstract published in the proceedings.
- 8.) Diagnostic and prognostic value of TTF-1 (thyroid transcription factor 1) immunohistochemistry in canine malignant lung tumors. G. Bettini, L. Marconato, M. Morini, F. Ferrari. VCS-ESVONC meeting, Copenhagen 28 February- 1 March 2008. Abstract published in the proceedings.
- 9.) Caspase-3 involvement in canine neoplastic mast-cells apoptosis induced by Imatinib mesylate. Rossi G, Magi E, Mari S, Marconato L, Renzoni G and Bertani C. VCS-ESVONC meeting, Copenhagen 28 February- 1 March 2008. published in the proceedings.
- 10.) Cancer risk linked to waste crisis in companion animals and their potential role as markers of effect: a hospital-based case-control study in the area of Naples (Italy). Laura Marconato, Chiara Leo, Rachele Girelli, Scilla Salvi, Francesca Abramo, Giuliano Bettini, Stefano Comazzi, Paolo Nardi,

Francesco Albanese, Eric Zini. Presented at the 18th Annual ECVIM-CA Congress, Ghent, Belgium, September 4-6th, 2008. Abstract published in the proceedings.

11.) Long term follow-up and predictors of survival in dogs with mammary inflammatory carcinoma: a retrospective analysis of 43 cases. Laura Marconato, Giorgio Romanelli, Damiano Stefanello, Claudio Giacoboni, Ugo Bonfanti, Giuliano Bettini, Riccardo Finotello, Sara Verganti, Paola Valenti, Luigia Ciaramella, Eric Zini. Presented at the ESVONC Annual Congress, Budapest, Hungary, 27-29th March 2009. Abstract published in the proceedings (p 32).

12.) Environmental dust exposure and lung cancer in dogs: evidence for a link. G Bettini, M Morini, L Marconato, PS Marcato, E Zini. ESVONC Annual Congress, Budapest, Hungary, 27-29th March 2009. Abstract published in the proceedings (p 34).

13.) Dogs with high-grade multicentric lymphoma surviving longer than 2 years: is cure possible? L. Marconato, D. Stefanello, P. Valenti, U. Bonfanti, S. Comazzi, P. Roccabianca, M. Caniatti, G. Romanelli, F. Massari, E. Zini. ESVONC Annual Congress, Torino, Italy, 18-20th March 2010. Abstract published in the proceedings (p 36).

14.) Canine medium macronucleated cell/ marginal zone lymphoma: description of 16 cases (2001-2008). P. Valenti, E. Zini, D. Stefanello, S. Comazzi, L. Marconato. ESVONC Annual Congress, Torino, Italy, 18-20th March 2010. Abstract published in the proceedings (p 13).

15.) Prognosis following surgical excision in canine and feline malignant skin tumors: the role of the histological evaluation of margins. F. Scarpa, S. Sabattini, O. Capitani, L. Marconato, P. Pintaldi, M. Morini, F. Ceccotto, G. Bettini. ESVONC Annual Congress, Torino, Italy, 18-20th March 2010. Abstract published in the proceedings (p 43).

16.) Role of glomerular filtration rate (GFR) to predict haematological toxicity in dogs receiving chemotherapy: a preliminary study. Finotello R, Lippi I, Meucci V, Marchetti V, Marconato L, Rota A, Cancedda S, Leone VF, Laganga P, Guidi G. ESVONC Annual Congress, Glasgow, Scotland, 24-26th March 2011. Abstract published in the proceedings (p 15).

17.) EGFR expression and air pollution carcinogenesis in canine primary lung tumors. Sabattini S, Mancini FR, Bacci B, Rossi F, Vignoli M, Marconato L, Bettini G. ESVONC Annual Congress, Glasgow, Scotland, 24-26th March 2011. Abstract published in the proceedings (p 20).

18.) Multimodal treatment approach for muscle-invasive transitional cell carcinoma of the urinary tract: a pilot study in 5 dogs. Marconato L, Buchholz J, Nitzl D, Keller M, Ruess-Melzer K, Kaser-Hotz B. ESVONC Annual Congress, Glasgow, Scotland, 24-26th March 2011. Abstract published in the proceedings (p 31).

19.) Evaluation of aberration in phenotype as prognostic factor in canine high-grade lymphoma. Leo C, Ruess-Melzer K, **Marconato L**, Valenti P, Comazzi S, Gelain ME, Kaser-Hotz B. ACVIM, June 15 - 18, 2011, Denver, CO, USA. Abstract published in the proceedings and JVIM 25:632-767, 2011.

20.) Combination of computed tomography-guided cementoplasty and radiation therapy for the treatment of lytic bone lesions in canine extremities. Preliminary study. Vignoli M, Rossi F, Rohrer-Bley C, Cancedda S, Laganga P, Stefanello D, Terragni R **Marconato L**. EAVDI November 11-12th 2011, Girton College, Cambridge, UK.

21.) Preliminary study on a combined doxorubicin-dacarbazine chemotherapeutic protocol for the adjuvant treatment of canine hemangiosarcoma. Finotello R, Marchetti V, Stefanello D, Zini E, Bettini G, Marconato L. 2nd World Veterinary Cancer Congress, March 1st-3rd, 2012, Paris. Abstract published in the proceedings (p 15).

22.) Clinical spectrum of canine lymphoma with histologic correlation according to the WHO classification- recognizing differences. Aresu L, Martini V, Rossi F, Vignoli M, Sampaolo M, Aricò A, Laganga P, Pierini A, Frayssinet P, Marconato L. ESVONC Annual Congress, Lisbon, Portugal, May 30th- June 1st, 2013. Abstract published in the proceedings (p 37).

23.) Epigenetic silencing of TFPI-2 is frequently detected in canine Diffuse Large B-cell Lymphoma. Ferraresso S, te Kronnie T, Bresolin S, Comazzi S, Gelain ME, Riondato F, Marconato L, Aresu L. ESVONC Annual Congress, Lisbon, Portugal, May 30th- June 1st, 2013. Abstract published in the proceedings (p 23).

24.) Concordance of mutational status in matched primary and metastatic canine dermal mast cell tumors: possible implications for clinical practice. Zorzan E, Dacasto M, Giantin M, Di Palma S, Cancedda S, Marconato L. ESVONC Annual Congress, Lisbon, Portugal, May 30th- June 1st, 2013. Abstract published in the proceedings (p 35).

25.) Transcriptomic analysis identified up-regulation of solute carrier transporters and UDP glucuronosyltransferases in dogs with aggressive cutaneous mast cell tumors. Giantin M, Baratto C, Marconato L, Vascellari M, Morello E, Vercelli A, Mutinelli F, Dacasto M, Granato A. ESVONC Annual Congress, Vienna, Austria, May 22nd- 24th, 2014. Abstract published in the proceedings (p 47).

26.) Clinical relevance of simultaneous histopathological grading of canine cutaneous mast cell tumors at first presentation: a retrospective study on 386 cases. Ferrari R, Buracco P, Stefanello D, Sabattini S, Finotello R, Giudice C, Grieco V, Iussich S, Scase T, Di Palma S, Bettini G, Martano M, Marconato L. ESVONC Annual Congress, Vienna, Austria, May 22nd- 24th, 2014. Abstract published in the proceedings (p 54).

27.) An open-label phase 1 dose-escalation clinical trial to determine the maximally tolerated dose and dose-limiting toxicities of a single intravenous gemcitabine administration in dogs with advanced solid tumors. Beatrice L, Finotello R, Dacasto M, Bonfanti U, Aresu L, Leone V, Pizzoni S, Furlanello T, Balestra G, Rohrer-Bley C, Marconato L. ESVONC Annual Congress, Vienna, Austria, May 22nd- 24th, 2014. Abstract published in the proceedings (p 60).

28.) Genetic heterogeneity of canine DLBCL by Oligonucleotide Array CGH. Aricò A, Ferraresso S, Marconato L, Bresolin S, te Kronnie G, Aresu L. ESVONC Annual Congress, Vienna, Austria, May 22nd- 24th, 2014. Abstract published in the proceedings (p 75).

29.) Coarse Fractionated Radiotherapy for Canine Soft Tissue Sarcoma: A Retrospective Study of 97 Cases Treated with 5x6Gy. Rohrer Bley C, Cancedda S, **Marconato L**, Stiborova K, Laganga P, Meier V, Leone V, Rossi F. ESVONC Annual Congress, Vienna, Austria, May 22nd- 24th, 2014. Abstract published in the proceedings (p 83).

30.) C-reactive protein, paraoxonase-1 and Alpha1-acid glycoprotein measurement in dogs with B- or T-cell lymphoma of different clinical stages. Giordano A, Rossi G, **Marconato L**, Stefanello D, Di Cesare F, Paltrinieri S. ESVCP Annual Congress, Milan, Italy, October 1-4th, 2014.

31.) Enhanced therapeutic effect of APAVAC vaccine in combination with dose-intense chemotherapy in dogs with clinically-advanced multicentric indolent B-cell lymphoma. **Marconato L**, Stefanello D, Sabattini S, Frayssinet P, Comazzi S, Riondato F, Laganga P, Pizzoni S, Rouquet N, Aresu L. ESVONC Annual Congress, Krakow, Poland, May 28th- 30th, 2015. Abstract published in the proceedings (p 42).

32.) Chemo-switch improves outcome in surgically-removed, biologically aggressive canine hemangiosarcoma. R. Finotello, J. Henriques, S. Sabattini, D. Stefanello, R. Felisberto, S. Pizzoni, R. Ferrari, **L. Marconato**. Annual Congress, Krakow, Poland, May 28th- 30th, 2015. Abstract published in the proceedings (p 36).

- 33.) Comparison of two radiation protocols for feline injection site sarcoma. Rossi F, **Marconato L**, Sabattini S, Cancedda S, Laganga P, Leone V, Rohrer Bley C. International Veterinary Radiology Meeting, Perth, Australia, August 16th- 21st, 2015.
- 34.) CANINE NODAL MARGINAL ZONE LYMPHOMA: DESCRIPTIVE INSIGHT INTO THE BIOLOGICAL BEHAVIOUR. Cozzi M, **Marconato L**, Martini V, Aresu L, Riondato F, Stefanello D, Comazzi S. 18th Conference of the European Society of Veterinary Clinical Pathology. Nantes, France, October 20-22nd, 2016.
- 35.) Detection and prognostic relevance of circulating and disseminated tumor cells in dogs with metastatic mammary carcinoma: a pilot study. **Marconato L**, Zamarchi R, Zanardello C, Facchinetti A, Rossi E, Capello K, Laganga P, Vascellari M. ESVONC Annual Congress, Lyon, France, April 20th- 22nd, 2017. Abstract published in the proceedings (p 36).
- 36.) Feline large granular lymphocyte lymphoma: an Italian Society of Veterinary Oncology (SIONCOV) retrospective study. Bettini G, Finotello R, Vasconi ME, Sabattini S, Agnoli C, Giacoboni C, Annoni M, Stefanello D, **Marconato L**. ESVONC Annual Congress, Lyon, France, April 20th- 22nd, 2017. Abstract published in the proceedings (p 30).
- 37.) Survival analysis of dogs with advanced primary pulmonary carcinoma treated by metronomic chemotherapy – a multicenter retrospective case-control study. Polton G, Finotello R, Sabattini S, Rossi F, Vasconi ME, Rohrer Bley C, **Marconato L**. ESVONC Annual Congress, Lyon, France, April 20th- 22nd, 2017. Abstract published in the proceedings (p 33).
- 38.) A Flow cytometric approach to Mast Cell Tumors in dogs. Sulcea M, **Marconato L**, Martano M, Iussich S, Leone VF, Dentini A, Miniscalco B, Melega M, Riondato F. ESVONC Annual Congress, Lyon, France, April 20th- 22nd, 2017. Abstract published in the proceedings (p 47).
- 39.) Mechanism of action of an autovaccine against cancer cells associating autologous tumor proteins to hydroxylapatite micro/nanoparticles. Frayssinet P, **Marconato L**, Rouquet N. ESVONC Annual Congress, Lyon, France, April 20th- 22nd, 2017. Abstract published in the proceedings (p 34).

KEY-NOTE PRESENTATIONS AT INTERNATIONAL SCIENTIFIC MEETINGS:

- 1.) How do we stage canine lymphoma today: resolving or complicating the controversy? Marconato L. ESVONC Annual Congress, Lisbon, Portugal, May 30th- June 1st, 2013. Abstract published in the proceedings (p 108-109).
- 2.) Role of immunotherapy- shaping the future? Marconato L. Workshop on canine lymphoma: state of the art and comparative aspects with human disease. 12th ICML congress, Lugano, Switzerland, June 22nd, 2013.
- 3.) Clinico-pathological management of canine lymphoma. Marconato L. Moscow, Russia, February 15th, 2014.
- 4.) Canine lymphoma: state of the art. **Marconato L**. Schweizerische Tierärztetage 2015, 6.-8. Mai 2015, Congress Centre Basel, Basel, Switzerland.
- 5.) Canine lymphoma: tips and tricks for daily practice. **Marconato L**. Schweizerische Tierärztetage 2015, 6.-8. Mai 2015, Congress Centre Basel, Basel, Switzerland.
- 6.) Mast cell tumors- always a challenge! **Marconato L**. Schweizerische Tierärztetage 2015, 6.-8. Mai 2015, Congress Centre Basel, Basel, Switzerland.

7.) Palladia & Co. –Tyrosine kinase inhibitors. **Marconato L.** Schweizerische Tierärztetage 2015, 6.-8. Mai 2015, Congress Centre Basel, Basel, Switzerland.

8.) Tumors of the urinary tract: occurrence and medical treatment. Marconato L. 25th ECVIM-CA Congress, 10-12 September, 2015, Lisbon, Portugal

9.) Staging of canine lymphoma: the controversy. **L. Marconato.** Czech Veterinary Oncologic Society, Hungarian Veterinary Oncologic Society and Veterinarian Oncologic Network Austria (VONA) Annual Congress, 7-8 October, 2016, Brno, Czech Republic.

10.) Management of progressive and recurrent canine lymphoma. **L. Marconato.** Czech Veterinary Oncologic Society, Hungarian Veterinary Oncologic Society and Veterinarian Oncologic Network Austria (VONA) Annual Congress, 7-8 October, 2016, Brno, Czech Republic.

11.) Monitoring of remission and personalised approach in canine lymphoma. **L. Marconato.** Czech Veterinary Oncologic Society, Hungarian Veterinary Oncologic Society and Veterinarian Oncologic Network Austria (VONA) Annual Congress, 7-8 October, 2016, Brno, Czech Republic.

12.) Immunotherapy and novel therapeutic approaches in canine lymphoma. **L. Marconato.** Czech Veterinary Oncologic Society, Hungarian Veterinary Oncologic Society and Veterinarian Oncologic Network Austria (VONA) Annual Congress, 7-8 October, 2016, Brno, Czech Republic.

13.) Indolent lymphoma- the state of the art in dogs. Marconato L, Polton G. Workshop on canine lymphoma: new developments in canine lymphoma. 14th ICML congress, Lugano, Switzerland, June 17th, 2017.

14.) Canine MZL: proposal for a multi-institutional clinical trial. Marconato L, Polton G. Workshop on canine lymphoma: new developments in canine lymphoma. 14th ICML congress, Lugano, Switzerland, June 17th, 2017.

MEMBERSHIPS OF PROFESSIONAL ASSOCIATIONS:

2003-current	Member of the Italian Cultural Veterinary Society for Companion Animals (SCIVAC)
2004-current	Member of the Veterinary Cancer Society (VCS)
2004-current	Member of the European Society of Veterinary Oncology (ESVONC)
2005-current	Member of the European Society of Veterinary Internal Medicine (ESVIM)
2006-current	President of the Italian Society of Veterinary Oncology (SIONCOV)
2011-current	ECVIM re-evaluation committee
2014-current	Chair of Working Group 2, European Canine Lymphoma Network
2014-current	Examiner of the General Practitioner Certificate in Oncology examination, ESVPS Examination Board

EDITORIAL POSITIONS:

Veterinary and Comparative Oncology	Invited ad hoc reviewer
The Canadian Veterinary Journal	Invited ad hoc reviewer
Veterinaria	Editorial board member (2007-current)

Reproduction in Domestic Animals	Invited ad hoc reviewer
Journal of Veterinary Internal Medicine	Invited ad hoc reviewer
Journal of Small Animal Practice	Invited ad hoc reviewer
The Veterinary Journal	Invited ad hoc reviewer
Vaccine	Invited ad hoc reviewer
Veterinary Immunology and Immunopathology	Invited ad hoc reviewer
Veterinary Pathology	Invited ad hoc reviewer
Veterinary Record	Invited ad hoc reviewer
BMC Veterinary Research	Editorial Board member